We believe that collaboration is a highly effective way to advance any treatment paradigm. We are excited to pursue collaboration opportunities, including the development of novel applications of our technology platform, RTGel reverse-thermal hydrogel, within urology, uro-oncology, and other therapeutic areas.

Are you interested in collaborating with UroGen?
Contact us

Current development collaborations

UroGen has an exclusive agreement with AbbVie to evaluate our RTGel across their toxin portfolio and broader pipeline.

In April 2019, UroGen entered into an agreement with Janssen Pharmaceuticals to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest.

UroGen and Janssen will each conduct certain activities under the terms of the agreement.